DermaSensor

by DermaSensor  · Based in United States → — AI Skin Cancer Detection & Melanoma Detection
Dermatology Family Medicine Internal Medicine

Monthly rental basis, with introductory pricing tiers.
Regulatory Status Disclosed

Overview

DermaSensor Inc. is a Miami-based connected medical device company dedicated to empowering healthcare professionals with clinically proven solutions for efficient skin cancer detection. It provides immediate, objective results to assist non-dermatologist physicians, primarily primary care physicians (PCPs), in making informed referral decisions for lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma. The device aims to improve early detection rates, increase access to vital healthcare, and ultimately save lives by providing objective data beyond what is visible to the naked eye.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered skin cancer detection
  • Elastic Scattering Spectroscopy (ESS) technology
  • Non-invasive, handheld device
  • Real-time, objective results ('Investigate Further' or 'Monitor')
  • 96% sensitivity for detecting melanoma, basal cell carcinoma, and squamous cell carcinoma
  • Wireless and ergonomically designed
  • Cloud integration for data storage
  • Automatic software updates
  • Reimbursement assistance available
  • Physician finder to locate clinics using DermaSensor

Use Cases

  • Assisting primary care physicians (PCPs) in evaluating suspicious skin lesions
  • Improving early detection of melanoma, basal cell carcinoma, and squamous cell carcinoma
  • Supporting referral decisions to dermatologists
  • Enhancing clinical confidence in skin cancer detection
  • Streamlining skin cancer assessment workflow in clinical settings
  • Providing objective data beyond visual assessment

What Physicians Need to Know

Evidence Base
DermaSensor utilizes Elastic Scattering Spectroscopy (ESS) and a locked, validated AI algorithm to analyze skin lesions. The device is supported by multiple prospective, multi-center studies, including the DERM-SUCCESS pivotal trial and the DERM-ASSESS III melanoma validation study. The device is intended to be used in conjunction with a clinical assessment, not as a standalone diagnostic tool.
Clinical Validation Studies
DermaSensor's performance is backed by several clinical studies. The DERM-SUCCESS pivotal study, involving 1,579 lesions from 1,005 patients across 22 primary care centers, demonstrated a 95.5% sensitivity in detecting all common skin cancers (melanoma, BCC, SCC) and a negative predictive value (NPV) of 96.6%. This study also showed that device sensitivity was superior to that of primary care physicians (PCPs) and non-inferior to a 90% performance goal based on dermatologist sensitivity. The DERM-ASSESS III study, a melanoma validation study conducted at 10 dermatology centers, found a 96% melanoma detection rate and a 98.1% NPV for melanoma. A clinical utility study with 108 PCPs and over 10,000 lesion assessments indicated that device use increased PCP management sensitivity from 82.0% to 91.4%, effectively halving false-negative referrals.
Override Rate Data
A clinical registry case study indicated that clinicians' decisions to further investigate tracked the DermaSensor spectral score, suggesting the score meaningfully informed management rather than overriding users' clinical judgment.
Differential Diagnosis Support
DermaSensor provides an objective risk assessment for melanoma, basal cell carcinoma, and squamous cell carcinoma, indicating whether a lesion should be monitored or investigated further. It does not differentiate between these cancer types when malignancy signs are present.
Guideline Update Frequency
The AI algorithm is locked and validated. DermaSensor plans to revalidate and periodically update the algorithm every few years, which requires resubmission to the FDA for clearance.
Clinical Workflow Integration
DermaSensor is designed for seamless integration into routine patient visits without disrupting existing clinical workflows. It is a handheld, point-of-care device that provides immediate results, supporting efficient assessment and decision-making. The process involves identifying a suspicious lesion, placing the device tip on it for five quick recordings, and receiving an immediate result. Training and support are provided to help practices integrate the device.
Decision Audit Trail
After an assessment, practices can access a Device Result Report in the DermaSensor Portal. This report can be customized with patient ID, lesion location, and risk factors, and then saved to the patient's medical record.
Physician Tip

DermaSensor is intended for use by physicians who are not dermatologists, in patients aged 40 and above, to assist in the decision to refer patients to a dermatologist for lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma. It should be used as an adjunctive tool in conjunction with a complete clinical assessment, including visual analysis of the lesion, and not as a standalone diagnostic or screening tool. The device provides a 'Monitor' or 'Investigate Further' result; 'Investigate Further' results include a spectral score from 1 to 10, with higher scores indicating a greater similarity to malignant characteristics. A 'Monitor' result has a high negative predictive value, meaning a low chance of being a false negative. For optimal use, ensure the device tip is placed perpendicularly on the lesion with slight indentation. The device requires calibration once per patient before use.

DermaSensor is designed to integrate into existing clinical workflows with minimal disruption. It is a standalone handheld device that provides immediate results at the point of care. While it generates a Device Result Report that can be saved to a patient's medical record, direct electronic medical record (EMR) integration details are not specified beyond saving a PDF. The company offers dedicated practice implementation support to assist with workflow integration.

Details

Category Clinical Decision Support & Reference, Dermatology AI
Pricing Monthly rental basis, with introductory pricing tiers.
DeploymentDevice
Compliance
BAA AvailableUnknown
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Dermatology, Family Medicine, Internal Medicine

Support & Reliability

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2024-01-12DEN230008 De NovoDermaSensor

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DermaSensor

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for DermaSensor.

View all on YouTube

Frequently Asked Questions

DermaSensor is an FDA-cleared, handheld, non-invasive device that uses Elastic Scattering Spectroscopy (ESS) and a locked AI algorithm to evaluate skin lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma in patients aged 40 and above. It provides an objective "Monitor" or "Investigate Further" result in real-time, helping physicians who are not dermatologists decide whether to refer a patient to a dermatologist. It is intended to support, not replace, clinical and visual assessment.
Clinical studies have shown DermaSensor to have a high sensitivity of 96% for detecting the three common skin cancers, with a negative predictive value (NPV) of 97% for ruling out malignancy. While it significantly improves primary care physicians' ability to identify and refer malignant lesions, it is not a diagnostic tool and should not be used as the sole criterion for diagnosis. Its specificity can be lower, which may lead to potentially unnecessary referrals.
DermaSensor is designed to integrate seamlessly into routine patient visits without disrupting clinical workflow. The device is used by the physician evaluating the suspicious lesion after their visual assessment, providing an objective result at the point of care. It requires no dedicated procedure room, extra staff, or extensive training courses.
While DermaSensor is the first and only FDA-cleared device that uses AI-driven technology to assist non-dermatologist physicians in evaluating lesions suggestive of the three common skin cancers, other technologies exist. Previous FDA-authorized AI-enabled dermatologic devices like MelaFind and Nevisense were limited in use to dermatologists and had challenges with specificity, cost, and workflow integration. Consumer smartphone apps for skin lesion analysis are not FDA-cleared for clinical diagnosis and operate under different standards.
DermaSensor is indicated for evaluating skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients aged 40 and above, to assist in the decision to refer the patient to a dermatologist. It is intended for use by physicians who are not dermatologists, such as family medicine physicians, internal medicine physicians, and community health physicians, in clinical settings. It is not intended for use as a screening tool or for patient self-use.

Related Tools

Stanford University
Stanford University
Clinical Decision Support & Reference
Stanford Online's "AI in Healthcare" program provides a comprehensive overview of artificial intelligence's applications and implications within the medical field.
RADIN Health
RADIN Health
Clinical Decision Support & Reference
RADINA is an AI-powered platform by RADIN Health designed to optimize radiology workflows, enhance diagnostic accuracy, and streamline reporting.
Med-PaLM 2
Google
Clinical Decision Support & Reference
Med-PaLM 2 is a large language model from Google, fine-tuned for healthcare to provide high-quality answers to medical questions and support clinical decision-making.
Pacmed Critical Discharge
Pacmed
Clinical Decision Support & Reference
Pacmed Critical Discharge is an AI tool that predicts the probability of death or readmission within seven days of ICU discharge, providing explainable insights for physicians.
AiZtech Labs
AiZtech Labs
Clinical Decision Support & Reference
AiZtech Labs provides enterprise-grade AI solutions for healthcare, focusing on operational efficiency, diagnostic accuracy, and patient care workflows for providers and health systems.
Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-05 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.